

# Takeshi Hatanaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8931520/publications.pdf>

Version: 2024-02-01

29  
papers

448  
citations

623574

14  
h-index

794469

19  
g-index

31  
all docs

31  
docs citations

31  
times ranked

393  
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan. <i>Cancer Medicine</i> , 2023, 12, 345-357.	1.3	5
2	Does first-line treatment have prognostic impact for unresectable HCC? Atezolizumab plus bevacizumab versus lenvatinib. <i>Cancer Medicine</i> , 2023, 12, 325-334.	1.3	25
3	Efficacy of Zinc Acetate Treatment for Patients with Decompensated Liver Cirrhosis Complicated by Hypozincemia. <i>Biological Trace Element Research</i> , 2022, 200, 497-504.	1.9	6
4	Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. <i>Cancer Reports</i> , 2022, 5, e1464.	0.6	43
5	A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 177-184.	0.4	7
6	Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era. <i>Oncology</i> , 2022, 100, 65-73.	0.9	3
7	Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. <i>Hepatology Research</i> , 2022, 52, 462-470.	1.8	18
8	Two cases of rapid progression of esophageal varices after atezolizumab+bevacizumab treatment for hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 451-459.	0.4	8
9	Successful Treatment of Pancreatic Fistula Following Surgery for Congenital Biliary Dilatation with Endoscopic Ultrasound-Guided Transduodenal Drainage. <i>Case Reports in Gastroenterology</i> , 2022, 16, 73-79.	0.3	0
10	Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria – Multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 308-316.	1.8	25
11	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis. <i>Cancer Medicine</i> , 2022, 11, 3796-3808.	1.3	21
12	A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab+bevacizumab treatment. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 776-783.	0.4	10
13	Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study. <i>Hepatology International</i> , 2022, 16, 1150-1160.	1.9	35
14	Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. <i>Oncology</i> , 2022, 100, 449-459.	0.9	3
15	Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. <i>Hepatology Research</i> , 2021, 51, 51-61.	1.8	20
16	The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study. <i>Oncology</i> , 2021, 99, 203-214.	0.9	18
17	Lenvatinib for Hepatocellular Carcinoma: A Literature Review. <i>Pharmaceuticals</i> , 2021, 14, 36.	1.7	30
18	Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study. <i>Oncology</i> , 2021, 99, 641-651.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. <i>Hepatology Research</i> , 2021, 51, 880-889.	1.8	15
20	Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study. <i>Internal Medicine</i> , 2021, 60, 2167-2174.	0.3	15
21	Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score. <i>JGH Open</i> , 2021, 5, 1183-1189.	0.7	21
22	Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. <i>Internal Medicine</i> , 2021, 60, 3061-3070.	0.3	1
23	Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure. <i>Hepatology Research</i> , 2020, 50, 303-312.	1.8	5
24	Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. <i>Hepatology Research</i> , 2020, 50, 382-395.	1.8	28
25	Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. <i>Cancers</i> , 2020, 12, 2906.	1.7	17
26	Efficacy and safety of 12-week sofosbuvir/velpatasvir treatment of patients with decompensated liver cirrhosis caused by hepatitis C virus infection. <i>Acta Hepatologica Japonica</i> , 2020, 61, 276-278.	0.0	2
27	Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study. <i>Internal Medicine</i> , 2019, 58, 1835-1844.	0.3	12
28	Factors predicting overall response and overall survival in hepatocellular carcinoma patients undergoing balloon-occluded transcatheter arterial chemoembolization: A retrospective cohort study. <i>Hepatology Research</i> , 2018, 48, 165-175.	1.8	13
29	Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2018, 10, 485-495.	0.8	31